Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO ...

This effort aligns with the objectives of Saudi Vision 2030, which aims to address the clinical and economic challenges posed ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to partner with other Big Pharma names?